Catalyst
Slingshot members are tracking this event:
Sarepta's (SRPT) Casimersen in Duchenne muscular dystrophy PDUFA date under priority review February 25, 2021
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SRPT |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 25, 2021
Occurred Source:
https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fda-approval-amondys-45tm
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Duchenne Muscular Dystrophy, Casimersen
